Results 81 to 90 of about 6,307 (191)

Detection of clinically significant drug-drug interactions in serotonin syndrome: a multisource real-world data and pharmacovigilance study. [PDF]

Ther Adv Drug Saf
Xu S, Song Z, Wang D, Li Y, Wang E, Bai J, Wang X.   +6 more
europepmc   +1 more source

Immune checkpoint inhibitors and myocarditis-myositis-myasthenia gravis overlap: a FAERS pharmacovigilance study with time-to-onset characterization. [PDF]

Front Pharmacol
Pacaci B, Yildirim B, Tunc MA, Demirel A, Akagunduz F, Kocaaslan E, Guren AK, Demircan NC, Bayoglu IV.   +8 more
europepmc   +1 more source

Sex-specific reporting patterns and onset timing of immune-related adverse events associated with nivolumab and pembrolizumab: a dual-database pharmacovigilance analysis. [PDF]

Front Immunol
Bai Y, Liu H, Meng H.
europepmc   +1 more source

Signal mining and analysis of adverse events in children using growth hormones: A retrospective real-world study based on FAERS. [PDF]

Medicine (Baltimore)
Xu W, Bao J, Fei Y.
europepmc   +1 more source

Triple-M Overlap Syndrome Associated with Immune Checkpoint Inhibitors: A FAERS Pharmacovigilance Analysis. [PDF]

Healthcare (Basel)
Alshamsan B, Ng TL.
europepmc   +1 more source

Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system. [PDF]

Front Immunol
Du K, Duan C, Zhang J, Zhang J, Du J, Pan Y, Liu Z, Zhang C, Zhang Y, Zhang Y, Zhang X, Sheng Z, Wang B, Ren Y, Zhu L.   +14 more
europepmc   +1 more source

Comparative post-marketing reporting signals of elagolix and myfembree in endometriosis: a FAERS pharmacovigilance study. [PDF]

Front Pharmacol
Bai M, Shen S, Chen JY.
europepmc   +1 more source

Comparative Analysis of Potential Side Effects of Targeted Oral Hypoglycemic Agents Using Spontaneous Adverse Event Reports and Social Media Data. [PDF]

Pharmacoepidemiol Drug Saf
Oh SH, Park DY, Song YK.
europepmc   +1 more source

Cardiovascular adverse events associated with bispecific antibodies in relapsed or refractory B-cell non-Hodgkin lymphomas. [PDF]

J Hematol Oncol
Munir M, Sayed A, Lee DH, Awan F, Ghazi S, Kim J, Addison D, Epperla N.   +7 more
europepmc   +1 more source

Comprehensive pharmacovigilance assessment of pairwise drug-drug interactions and acute pancreatitis in the FDA adverse event reporting system: focus on incretin-based drugs. [PDF]

Front Drug Saf Regul
Kazume I, Onda K, Tanaka S, Yokokawa T, Suzuki K.   +4 more
europepmc   +1 more source